Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Inflammation
Published in: Journal of Inflammation 1/2014

Open Access 01-12-2014 | Research

The combination of red palm oil and rooibos show anti-inflammatory effects in rats

Authors: Emma Katengua-Thamahane, Jeanine L Marnewick, Olawale R Ajuwon, Novel N Chegou, Gergő Szűcs, Péter Ferdinandy, Tamás Csont, Csaba Csonka, Jacques Van Rooyen

Published in: Journal of Inflammation | Issue 1/2014

Login to get access

Abstract

Background

Red palm oil (RPO) and rooibos have been shown to exhibit cardioprotective properties. RPO is rich in essential fatty acids and fat soluble antioxidants while rooibos contains polyphenolic compounds with a unique composition of flavonoids. They exert their biological effects in different cellular compartments. Therefore the combination of these two natural food compounds has the potential to enhance the spectrum of available dietary antioxidants in different cellular compartments, which could result in an enhanced protection against certain pathological conditions such as inflammation.

Methods

Male Wistar rats weighing 150-200 g were supplemented with RPO, rooibos or their combination for 28 days. The Langendorff system and the lipoposaccharide (LPS)-induced inflammatory model were used to establish if RPO and rooibos, when supplemented alone or in combination, will reverse the negative effects of LPS on cardiac function at baseline. The effect of dietary intervention was also investigated on modulation of pro-inflammatory and anti-inflammatory cytokines in plasma and myocardial tissue.

Results and discussion

The LPS resulted in induction of systemic inflammation as evidenced by increased levels of IL-1β in plasma of LPS-treated rats compared to their non-treated control counterparts. Dietary supplementation and LPS treatment did not have an effect on baseline cardiac functional parameters. However, the elevation of IL-1β levels in plasma of LPS-induced rats consuming either RPO or rooibos alone were paralleled with increased levels of the anti-inflammatory cytokine, IL-10. The combination of rooibos and RPO was associated with enhanced endogenous production of myocardial IL-10 in LPS-induced rats.

Conclusion

The results of this study indicate that RPO and rooibos when supplemented individually showed anti-inflammatory effect at systemic level while their combination exhibited an enhanced anti-inflammatory effect in the myocardial tissue. Therefore, the findings in the current study argue that the combination of these two natural food substances could be beneficial in clinically relevant conditions where inflammation plays a role.
Appendix
Available only for authorised users
Literature
1.
Halliwell B: Free radicals and antioxidants - quo vadis?. Trends Pharmacol Sci. 2011, 32 (3): 125-130. 10.1016/j.tips.2010.12.002.PubMedCrossRef
2.
Pantsi WG, Marnewick JL, Esterhuyse AJ, Rautenbach F, Van Rooyen J: Rooibos (Aspalathus linearis) offers cardiac protection against ischaemia/reperfusion in the isolated perfused rat heart. Phytomedicine. 2011, 18: 1220-1228. 10.1016/j.phymed.2011.09.069.PubMedCrossRef
3.
Esterhuyse AJ, van Rooyen J, Strijdom H, Bester D, du Toit EF: Proposed mechanisms for red palm oil induced cardioprotection in a model of hyperlipidaemia in the rat. Prostaglandins Leukot Essent Fatty Acids. 2006, 75: 375-384. 10.1016/j.plefa.2006.07.001.PubMedCrossRef
4.
Engelbrecht AM, Esterhuyse AJ, du Toit EF, Lochner A, van Rooyen J: p38-MAPK and PKB/Akt, possible role players in red palm oil-induced protection of the isolated perfused rat heart?. J Nutr Biochem. 2006, 17 (4): 265-271. 10.1016/j.jnutbio.2005.05.001.PubMedCrossRef
5.
Engelbrecht AM, Odendaal L, du Toit EF, Kupai K, Tamás C, Ferdinandy P, van Rooyen J: “The effect of dietary red palm oil on the functional recovery of the ischaemic/reperfused isolated rat heart: the involvement of the PI3-Kinase signaling pathway. Lipids Health Dis. 2009, 8: 1-8. 10.1186/1476-511X-8-18.CrossRef
6.
van Rooyen J, Esterhuyse AJ, Engelbrecht AM, du Toit EF: Health benefits of a natural carotenoid rich oil: a proposed mechanism of protection against ischaemia/reperfusion injury. Asia Pac J Clin Nutr. 2008, 17 (S1): 316-319.PubMed
7.
Bester DJ, Kupai K, Csont T, Szucs G, Csonka C, Esterhuyse AJ, Ferdinandy P, Van Rooyen J: Dietary red palm oil supplementation reduces myocardial infarct size in an isolated perfused rat heart model. Lipids Health Dis. 2010, 9 (64): 1-9.
8.
Bačová Barbara J, Viczenczová C, Knezl V, Dosenko V, Beňova T, Navarová J, Gonçalvesová E, van Rooyen J, Weismann P, Slezák J, Narcis T: Up-regulation of myocardial connexin-43 in spontaneously hypertensive rats fed red palm oil is most likely implicated in its ant-arrhythimic effects. Can J Physio Phamarcol. 2012, 90: 1235-1245. 10.1139/y2012-103.CrossRef
9.
Ajuwon OR, Katengua-Thamahane E, Van Rooyen J, Oguntibeju O, Marnewick JL: Protective Effects of Rooibos (Aspalathus linearis) and/or Red Palm Oil (Elaeis guineensis) Supplementation on tert-Butyl Hydroperoxide-Induced Oxidative Hepatotoxicity in Wistar Rats. Evid-Based Compl Alt. 2013, 2013: 984273-10.1155/2013/984273.CrossRef
10.
Hariharan K, Purushothama S, Raina PL: Studies on the red palm oil: Effect of partial supplementation of saturated fats upon lipids and lipoproteins. Nutr Res. 1996, 16 (8): 1381-1392. 10.1016/0271-5317(96)00145-5.CrossRef
11.
Kritchevsky D, Tepper SA, Kuksis A, Wright S, Czarnecki SK SK: Cholesterol Vehicle in experimental Atherosclerosis. 22. Refined, Bleached, Deodorized (RBD) Palm oil, Randomized palm oil and red palm oil. Nutr Res. 2000, 20 (6): 887-892. 10.1016/S0271-5317(00)00166-4.CrossRef
12.
Nagendran B, Unnithan UR, Choo YM, Sundram K: Characteristics of red palm oil, a carotene- and vitamin E–rich refined oil for food uses. Food Nutr Bull. 2000, 21 (2): 189-194.CrossRef
13.
Sundram K, Sambanthamurthi R, Tan Y: Palm fruit chemistry and nutrition. Asia Pacific J Clin Nutr. 2003, 12 (3): 355-362.
14.
Sambanthamurthi R, Sundram K, Tan YA: Chemistry and biochemistry of palm oil. Prog Lipid Res. 2000, 39 (6): 507-558. 10.1016/S0163-7827(00)00015-1.PubMedCrossRef
15.
Packer L, Weber SU, Rimbach G: Molecular aspects of a-tocotrienol antioxidant action and cell signalling. J Nutr. 2001, 131: 369S-373S.PubMed
16.
Theriault A, Chao JT, Wang Q, Gapor A, Adeli K: Tocotrienol; A review of its therapeutic potential. Clin Biochem. 1999, 32: 309-319. 10.1016/S0009-9120(99)00027-2.PubMedCrossRef
17.
Sen CK, Rink C, Khanna S: Palm oil-derived natural vitamin E alpha tocotrienol in brain health and disease. J Am Coll Nutr. 2010, 29: S314-S323. 10.1080/07315724.2010.10719846.CrossRef
18.
Aggarwal BB, Sundaram C, Prasad R: Kannappan. Tocotrienols, the vitamin E of the 21st century: its potential against cancer and other chronic diseases. Biochem Pharmacol. 2010, 80: 1613-1631. 10.1016/j.bcp.2010.07.043.PubMedPubMedCentralCrossRef
19.
Jiang Q, Elson-Schwab I, Courtemanche Ames BN C: γ-Tocopherol and its major metabolite, in contrast to α-tocopherol, inhibit cyclooxygenase activity in macrophages and epithelial cells. Proc Natl Acad Sci U S A. 2000, 97 (21): 11494-11499. 10.1073/pnas.200357097.PubMedPubMedCentralCrossRef
20.
Theriault A, Chao JT, Gapor A: Tocotrienol is the most effective vitamin E for reducing endothelial expression of adhesion molecules and adhesion to Monocytes. Atherosclerosis. 2002, 160: 21-23. 10.1016/S0021-9150(01)00540-8.PubMedCrossRef
21.
Jiang Q, Ames BN: γ-Tocopherol, but not α-tocopherol, decreases proinflammatory eicosanoids and inflammation damage in rats. FASEB J. 2003, 17: 816-822. 10.1096/fj.02-0877com.PubMedCrossRef
22.
Noguchi N, Hanyu R, Nonaka A, Okimoto Y, Kodama T: Inhibition of THP-1 cell adhesion to endothelial cell by α-tocopherol and α-tocotrienol is dependent on intracellular concentration of the antioxidants. Free Radic Biol Med. 2003, 34 (12): 1614-1620. 10.1016/S0891-5849(03)00216-8.PubMedCrossRef
23.
McKay DL, Blumberg JB: Review of the bioactivity of south african herbal teas: rooibos (Aspalathus linearis) and honeybush (Cyclopia intermedia). Phytother Res. 2007, 21: 1-16. 10.1002/ptr.1992.PubMedCrossRef
24.
Joubert E, Gelderblom WCA, Louw A, de Beer D: South African herbal teas: Aspalathus linearis. Cyclopia spp. and Athrixia Phylicoides-A review. J Ethnopharmacol. 2008, 119: 376-412. 10.1016/j.jep.2008.06.014.PubMedCrossRef
25.
Marnewick JL: Rooibos and honeybush: recent advances in chemistry, biological activity and pharmacognosy. African Natural Plant Products: New Discoveries and Challenges in Chemistry and Quality. Edited by: Juliana HR, Simon JE, Ho C-T. 2009, Oxford University Press, Oxford, United Kingdom, 277-294.
26.
Duthie GG, Gardner PT, Kyle JAM: Plant polyphenols: are they the new magic bullet?. Proc Nutr Soc. 2003, 62: 599-603. 10.1079/PNS2003275.PubMedCrossRef
27.
Joubert E, Winterton P, Britz TJ, Ferreira D: Superoxide anion and a; a-diphenyl-b-picrylhydrazyl radical scavenging capacity of rooibos (Aspalathus linearis) aqueous extracts, crude phenolic fractions, tannin and flavonoids. Food Res Int. 2004, 37: 133-138. 10.1016/j.foodres.2003.09.011.CrossRef
28.
Liu CM, Zheng YL, Lu J, Zhang ZF, Fan SH, Wu DM, Ma JQ: Quercetin protects rat liver against lead-induced oxidative stress and apoptosis. Environ Toxicol Pharmacol. 2010, 29: 158-166. 10.1016/j.etap.2009.12.006.PubMedCrossRef
29.
Nikolova V, Petrova S, Petkova V, Pavlova S, Michailova A, Georgieva T: Antioxidant effects of rooibos tea on workers occupationally exposed to lead. Toxicol Lett. 2007, 172: S120-S121. 10.1016/j.toxlet.2007.05.320.CrossRef
30.
Kawano A, Nakamura H, Hata S, Minakawa M, Miura Y, Yagasaki K: Hypoglycemic effect of aspalathin, a rooibos tea component from Aspalathus linearis, in type 2 diabetic model db/db mice. Phytomedicine. 2009, 16: 437-443. 10.1016/j.phymed.2008.11.009.PubMedCrossRef
31.
Schulz H, Joubert E, Schütze W: Quantification of quality parameters for reliable evaluation of green rooibos (Aspalathus linearis). Eur Food Res Technol. 2003, 216: 539-543.
32.
Marnewick JL, Joubert E, Joseph S, Swanevelder S, Swart P, Gelderblom W: Inhibition of tumour promotion in mouse skin by extracts of rooibos (Aspalathus linearis) and honeybush (Cyclopia intermedia), unique South African herbal teas. Cancer Lett. 2005, 224: 193-202. 10.1016/j.canlet.2004.11.014.PubMedCrossRef
33.
Baba H, Ohtsuka Y, Haruna H, Lee T, Nagata S, Maeda M, Yamashiro Y, Shimizu T: Studies of anti-inflammatory effects of Rooibos tea in rats. Pediatr Int. 2009, 51: 700-704. 10.1111/j.1442-200X.2009.02835.x.PubMedCrossRef
34.
Villaño D, Pecorari M, Testa MF, Raguzzini A, Stalmach A, Crozier A, Tubili C, Serafini M: Unfermented and fermented rooibos teas (Aspalathus linearis) increase plasma total antioxidant capacity in healthy humans. Food Chem. 2010, 123: 679-683. 10.1016/j.foodchem.2010.05.032.CrossRef
35.
Persson IAL, Persson K, Hägg S, Anderson RGG: Effects of green tea, black tea and rooibos tea on angiotensin-converting enzyme and nitric oxide in healthy volunteers. Publ Health Nutr. 2010, 13 (5): 730-737. 10.1017/S1368980010000170.CrossRef
36.
Persson IAL: The pharmacological mechanism of angiotensin-converting enzyme inhibition by green tea, rooibos and enalaprilat - a study on enzyme kinetics. Phytother Res. 2012, 26: 517-521. 10.1002/ptr.3588.PubMedCrossRef
37.
Marnewick JL, Rautenbach F, Venter I, Neethling H, Blackhurst DM, Wolmarans P, Macharia M: Effects of rooibos (Aspalathus linearis) on oxidative stress and biochemical parameters in adults at risk for cardiovascular disease. J Ethnopharmacol. 2011, 133: 46-52. 10.1016/j.jep.2010.08.061.PubMedCrossRef
38.
Petrova A, Davids LM, Rautenbach F, Marnewick JL: Photoprotection by honeybush extracts, hesperidin and mangiferin against UVB-induced skin damage in SKH-1 mice. J. Photochem Photobiol B. 2011, 103: 126-139. 10.1016/j.jphotobiol.2011.02.020.PubMedCrossRef
39.
Uličná O, Vančova O, Božek P, Cársky J, Sebeková K, Boor P, Nakano M, Greksák M: Rooibos tea (Aspalathus linearis) partially prevents oxidative stress in streptozotocin-induced diabetic rats. Physiol Res. 2006, 55: 157-164.PubMed
40.
Joubert E: HPLC quantification of the dihydrochalcones, aspalathin and nothofagin in rooibos tea (Aspalathus linearis) as affected by processing. Food Chem. 1996, 55 (4): 40-11. 10.1016/0308-8146(95)00166-2.CrossRef
41.
Willerson JT, Ridker PM: Inflammation as a cardiovascular risk factor. Circulation. 2004, 109: II2-II10. 10.1161/01.CIR.0000122867.89751.59.PubMedCrossRef
42.
Libby P: Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr. 2006, 83: 456S-460S.PubMed
43.
Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB: Risk of myocardial infarction in patients with psoriasis. JAMA. 2006, 296: 1735-1741. 10.1001/jama.296.14.1735.PubMedCrossRef
44.
Balkwill F, Mantovani A: Inflammation and cancer: back to Virchow?. Lancet. 2001, 357: 539-545. 10.1016/S0140-6736(00)04046-0.PubMedCrossRef
45.
Wallberg-Jonsson S, Johansson H, Ohman ML, Rantapaa- Dahlqvist S: Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. J Rheumatol. 1999, 26 (12): 2562-2571.PubMed
46.
Callow AD: Cardiovascular disease 2005-the global picture. Vasc Pharmacol. 2006, 45 (5): 302-307. 10.1016/j.vph.2006.08.010.CrossRef
47.
Haines DD, Varga B, Bak I, Juhasz B, Mahmoud FF, Kalantari H, Gesztelyi R, Lekli I, Czompa A, Tosaki A: Summative interaction between astaxanthin, Ginkgo biloba extract (EGb761) and vitamin C in suppression of respiratory infl ammation: a comparison with ibuprofen. Phytother Res. 2011, 25: 128-136. 10.1002/ptr.3160.PubMedCrossRef
48.
Delgado J, del Pilar TM, Garrido M, Barriga C, Paredes SD, Espino J, Rodríguez AB: Systemic Inflammatory load in young and old ringdoves is modulated by consumption of a Jerte Valley Cherry-Based Product. J Med Food. 2012, 15 (8): 707-712. 10.1089/jmf.2011.0233.PubMedPubMedCentralCrossRef
49.
Zhou Z, Nair MG, Claycombe KJ: Synergistic inhibition of interleukin-6 production in adipose stem cells by tart cherry anthocyanins and atorvastatin. Phytomedicine. 2012, 19: 878-881. 10.1016/j.phymed.2012.05.001.PubMedCrossRef
50.
Mahmoud FF, Al-Awadhi R, Haines DD, Dashti A, Dashti H, Al-Ozairi E, Bak I, Tosaki A: Sour Cherry Seed Kernel Extract increases Heme Oxygenase-1 expression and decreases representation of CD3+ TNF-α + and CD3+ IL-8+ subpopulations in peripheral blood leukocyte cultures from Type 2 Diabetes patients. Phytother Res. 2013, 27: 767-774. 10.1002/ptr.4783.PubMedCrossRef
51.
Ohsaki Y, Shirakawa H, Hiwatashi K, Furukawa Y, Mizutani T, Komal M: Vitamin K suppresses lipopolysaccharide-induced inflammation in the rat. Biosci Biotechnol Biochem. 2006, 70 (4): 926-932. 10.1271/bbb.70.926.PubMedCrossRef
52.
Du J, An J, Wei N, Guan T, Pritchard KA, Shi Y: Increased resistance to LPS-induced myocardial dysfunction in the Brown Norway Rats versus Dahl S Rats: Role of inflammatory cytokines and nuclear factor kB pathway. Shock. 2010, 33 (3): 332-336. 10.1097/SHK.0b013e3181b7819e.PubMedPubMedCentralCrossRef
53.
Medzhitov R, Janeway CA: Innate immunity: impact on the adaptive immune response. Curr Opin Immunol. 1997, 9: 4-9. 10.1016/S0952-7915(97)80152-5.PubMedCrossRef
54.
Zeuke S, Ulmerb AJ, Kusumoto S, Katus HA, Heine H: TLR4-mediated inflammatory activation of human coronary artery endothelial cells by LPS. Cardiovasc Res. 2002, 56: 126-134. 10.1016/S0008-6363(02)00512-6.PubMedCrossRef
55.
Kelly RA, Smith TW: Cytokines and cardiac contractile function. Circulation. 1997, 95: 778-781. 10.1161/01.CIR.95.4.778.PubMedCrossRef
56.
Marnewick JL, Joubert E, Swart P, Der Westhuizen FV, Gelderblom WC: Modulation of hepatic drug metabolizing enzymes and oxidative status by rooibos (Aspalathus linearis) and honeybush (Cyclopia intermedia), green and black (Camellia sinensis) teas in rats. J Agricult Food Chem. 2003, 51 (27): 8113-8119. 10.1021/jf0344643.CrossRef
57.
Bradford MM: A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976, 71: 248-254. 10.1016/0003-2697(76)90527-3.CrossRef
58.
Kadokami T, Mctiernan CF, Kubota T, Frye CS, Bounoutas GS, Robbins PD, Watkins SC, Feldman AM: Effects of soluble TNF receptor treatment on lipopolysaccharide-induced myocardial cytokine expression. Am J Physiol Heart Circ Physiol. 2001, 280: H2281-H2291.PubMed
59.
Gruys E, Toussaint MJM, Niewold T, Koopmans SJ: Acute phase reaction and acute phase proteins. Zhejiang Univ SCI. 2005, 6B (11): 1045-1056. 10.1631/jzus.2005.B1045.CrossRef
60.
Fearon WF, Fearon DT: Inflammation and cardiovascular disease; role of the interleukin-1 receptor antagonist. Circulation. 2008, 117: 2577-2579. 10.1161/CIRCULATIONAHA.108.772491.PubMedCrossRef
61.
Qureshi ST, Larivière L, Leveque G, Clermont S, Moore KJ, Gros P, Malo D: Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (Tlr4). J Exp Med. 1999, 189 (4): 615-625. 10.1084/jem.189.4.615.PubMedPubMedCentralCrossRef
62.
Frantz S, Kobzik L, Kim YD, Fukazawa R, Medzhitov R, Lee RT, Kelly RA: Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J Clin Invest. 1999, 104: 271-280. 10.1172/JCI6709.PubMedPubMedCentralCrossRef
63.
64.
Akira S: Toll-like receptor signaling. J Biol Chem. 2003, 278 (40): 38105-38108. 10.1074/jbc.R300028200.PubMedCrossRef
65.
Sweet MJ, Hume DA: Endotoxin signal transduction in macrophages. J Leukoc Biol. 1996, 60 (1): 8-26.PubMed
66.
Feng Y, Zhao H, Xu X, Buys ES, Raher MJ, Bopassa JC, Thibault H, Scherrer-Crosbie M, Schmidt U, Chao W: Innate immune adaptor MyD88 mediates neutrophil recruitment and myocardial injury after ischemia-reperfusion in mice. Am J Physiol Heart Circ Physiol. 2008, 295: H1311-H1318. 10.1152/ajpheart.00119.2008.PubMedPubMedCentralCrossRef
67.
Chao W: Toll-like receptor signaling: a critical modulator of cell survival and ischemic injury in the heart. Am J Physiol Heart Circ Physiol. 2009, 296: H1-H12. 10.1152/ajpheart.00995.2008.PubMedPubMedCentralCrossRef
68.
Irwin MW, Mak S, Mann DL, Qu R, Penninger JM, Yan A, Dawood F, Wen WH, Shou Z, Liu P: Tissue expression and immunolocalization of tumor necrosis factor-alpha in postinfarction dysfunctional myocardium. Circulation. 1999, 99: 1492-1498. 10.1161/01.CIR.99.11.1492.PubMedCrossRef
69.
Damas P, Ledoux D, Nys M, Vrindts Y, De Groote D, Franchimont P, Lamy M: Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann Surg. 1992, 215: 356-362. 10.1097/00000658-199204000-00009.PubMedPubMedCentralCrossRef
70.
Steensberg A, Fischer CP, Keller C, Moller K, Pedersen BK: IL-6 enhances plasma IL-1ra, IL-10, cortisol in humans. Am J Physiol Endocrinol Metab. 2003, 285: E433-E437.PubMedCrossRef
71.
Xing Z, Gauldie J, Cox G, Baumann H, Jordana M, Lei XF, Achong MK: IL-6 is an anti-inflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest. 1998, 101: 311-320. 10.1172/JCI1368.PubMedPubMedCentralCrossRef
72.
Tilg H, Trehu E, Atkins MB, Dinarello CA, Mier JW: Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood. 1994, 1 (83): 113-118.
73.
Yasukawa H, Ohishi M, Mori H, Murakami M, Chinen T, Aki D, Hanada T, Takeda K, Akira S, Hoshijima M, Hirano T, Chien KR, Yoshimura A: IL6 induces an antiinflammatory response in the absence of SOCS3 in macrophages. Nat Immunol. 2003, 4: 551-556. 10.1038/ni938.PubMedCrossRef
74.
Choy EH, Isenberg DA, Garrood T, Farrow S, Ioannou Y, Bird H, Cheung N, Williams B, Hazleman B, Price R, Yoshizaki K, Nishimoto N, Kishimoto T, Panayi GS: Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum. 2002, 46: 3143-3150. 10.1002/art.10623.PubMedCrossRef
75.
Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Hashimoto J, Azuma J, Kishimoto T: Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis & Rheum. 2004, 50 (6): 1761-1769. 10.1002/art.20303.CrossRef
76.
Rennick DM, Fort MM, Davidson NJ: Studies with IL-10−/− mice: an overview. J Leukoc Biol. 1997, 61: 389-396.PubMed
77.
Heumann D, Galley P, Barras C, Zaech P, Ulevitch RJ, Tobias PS, Glauser MP, Baumgartner JD: Control of lipopolysaccharide (LPS) binding and LPS-induced tumor necrosis factor secretion in human peripheral blood monocytes. J Immunol. 1992, 148: 3505-3512.PubMed
78.
Rabe C, Steenkamp JA, Joubert E, Burger JFW, Ferrema D: Phenolic metabolites from rooibos tea (Aspalathus Linearis). Phytochemistry. 1994, 35 (6): 1559-1565. 10.1016/S0031-9422(00)86894-6.CrossRef
79.
Rotelli AE, Guardia T, Juárez AO, de la Rocha NE, Pelzer LE: Comparative study of flavonoids in experimental models of inflammation. Pharmacol Res. 2003, 48: 601-606. 10.1016/S1043-6618(03)00225-1.PubMedCrossRef
80.
Wang L, Tu YC, Lian TW, Hung JT, Yen JH, Wu MJ: Distinctive antioxidant and anti-inflammatory effects of flavonols. J Agric Food Chem. 2006, 54: 9798-9804. 10.1021/jf0620719.PubMedCrossRef
81.
Crouvezier S, Powell B, Keir D, Yaqoob P: The effects of phenolic components of tea on the production of pro- and anti-inflammatory cytokines by human leukocytes in vitro. Cytokine. 2001, 13: 280-286. 10.1006/cyto.2000.0837.PubMedCrossRef
82.
Kim HP, Kun HS, Chang HW, Kang SS: Anti-inflammatory plant flavonoids and cellular action mechanisms. J Pharmacol Sci. 2004, 96: 229-245. 10.1254/jphs.CRJ04003X.PubMedCrossRef
83.
Comalada M, Ballester I, Bailon E, Sierra S, Xaus J, Gálvez J, de Medina FS, Zarzuelo A: Inhibition of pro-inflammatory markers in primary bone marrow-derived mouse macrophages by naturally occurring flavonoids: analysis of the structure-activity relationship. Biochem Pharmacol. 2006, 72: 1010-1021. 10.1016/j.bcp.2006.07.016.PubMedCrossRef
84.
Mutalib MSA, Khaza’ai H, Wahle KWJ: Palm-tocotrienol rich fraction (TRF) is a more effective inhibitor of LDL oxidation and endothelial cell lipid peroxidation than α-tocopherol in vitro. Food Res Int. 2003, 36: 405-413. 10.1016/S0963-9969(02)00173-4.CrossRef
85.
Conner EM, Grisham MB: Inflammation, free radicals, and antioxidants. Nutrition. 1996, 12: 274-277. 10.1016/S0899-9007(96)00000-8.PubMedCrossRef
86.
Ceriello A, Motz E: Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol. 2004, 24: 816-823. 10.1161/01.ATV.0000122852.22604.78.PubMedCrossRef
87.
Jones SP, Trocha SD, Lefer DJ: Cardioprotective actions of endogenous IL-10 are independent of iNOS. Am J Physiol Heart Circ Physiol. 2001, 281: H48-H52.PubMed
88.
Yang Z, Zingarelli B, Szabo C: Crucial role of endogenous interleukin-10 production in myocardial ischemia/reperfusion injury. Circulation. 2000, 101: 1019-1026. 10.1161/01.CIR.101.9.1019.PubMedCrossRef
89.
Rietschel ET, Brade H: Bacterial endotoxins. Sci Am. 1992, 267: 53-61. 10.1038/scientificamerican0892-54.CrossRef
90.
Wang YP, Sato C, Mizoguchi K, Yamashita Y, Maeta MOH: Lipopolysaccharide triggers late preconditioning against myocardial infarction via inducible nitric oxide synthase. Cardiovasc Res. 2002, 56: 33-42. 10.1016/S0008-6363(02)00506-0.PubMedCrossRef
91.
Yao YW, Zhang GH, Zhang YY, Li WD, Wang CH, Yin CY, Zhang FM: Lipopolysaccharide pretreatment protects against ischemia/reperfusion injury via increase of HSP70 and inhibition of NF-κB. Cell Stress Chaperon. 2011, 16: 287-296. 10.1007/s12192-010-0242-6.CrossRef
92.
Lew WYW, Bayna E, Molle ED, Dalton ND, Lai NC, Bhargava V, Mendiola V, Clopton P, Tang T: Recurrent exposure to subclinical lipopolysaccharide increases mortality and induces cardiac fibrosis in mice. PLoS One. 2013, 8 (4): e61057-10.1371/journal.pone.0061057.PubMedPubMedCentralCrossRef
93.
Yao Y, Zhang F, Wang L, Zhang G, Wang Z, Chen J, Gao X: Lipopolysaccharide preconditioning enhances the efficacy of mesenchymal stem cells transplantation in a rat model of acute myocardial infarction. J Biosoc Sci. 2009, 16 (74): 1-11.
94.
Lastres-Becker I, Molina-Holgado FJ: Endotoxin preconditioning protects neurons from in vitro ischemia: role of endogenous IL-1beta and TNF-alpha. J Neuroimmunol. 2006, 173: 108-116. 10.1016/j.jneuroim.2005.12.006.PubMedCrossRef
95.
Rosenzweig HL, Minami M, Lessov NS, Coste SC, Stevens SL, Henshall DC, Meller R, Simon RP, Stenzel-Poore MP: Endotoxin preconditioning protects against the cytotoxic effects of TNFalpha after stroke: a novel role for TNFalpha in LPS-ischemic tolerance. J Cereb Blood Flow Metab. 2007, 27 (10): 1663-1674. 10.1038/sj.jcbfm.9600464.PubMedCrossRef
Metadata
Title
The combination of red palm oil and rooibos show anti-inflammatory effects in rats
Authors
Emma Katengua-Thamahane
Jeanine L Marnewick
Olawale R Ajuwon
Novel N Chegou
Gergő Szűcs
Péter Ferdinandy
Tamás Csont
Csaba Csonka
Jacques Van Rooyen
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Journal of Inflammation / Issue 1/2014
Electronic ISSN: 1476-9255
DOI
https://doi.org/10.1186/s12950-014-0041-4

Other articles of this Issue 1/2014

Journal of Inflammation 1/2014 Go to the issue

Research

Early effects of Staphylococcus aureus biofilm secreted products on inflammatory responses of human epithelial keratinocytes

Research

The histone deacetylase Hdac1 regulates inflammatory signalling in intestinal epithelial cells

Short Report

Apoptotic cell administration is detrimental in murine renal ischaemia reperfusion injury

Research

Upregulation of ICAM-1 in diabetic rats after transient forebrain ischemia and reperfusion injury

Research

A cardiopulmonary bypass with deep hypothermic circulatory arrest rat model for the investigation of the systemic inflammation response and induced organ damage

Research

P2X7 receptors are a potential novel target for anti-glioma therapies
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits